



Dryden Regional Health Centre

58 GOODALL STREET, P.O. BOX 3003, DRYDEN, ONTARIO P8N 2Z6

TELEPHONE (807)223-8200 FAX (807)223-8628

Respect • Integrity • Humility • Compassion • Accountability

APPENDIX C – ATTESTATION

Prepared in accordance with section 15 of the *Broader Public Sector Accountability Act, 2010 (BPSAA)*

TO: The Board of Directors of Dryden Regional Health Centre, (the “Board”)

FROM: Doreen Armstrong-Ross
President & CEO
Dryden Regional Health Centre

Date: June 23, 2025

RE: April 1, 2024 to March 31, 2025 (“the Applicable Period”)

On behalf of the Dryden Regional Health Centre (the Hospital) I attest to:

- the completion and accuracy of reports required of the Hospital pursuant to section 6 of the BPSAA on the use of consultants;
- the Hospital’s compliance with the prohibition in section 4 of the BPSAA on engaging lobbyist services using public funds;
- the Hospital’s compliance with any applicable expense claims directives issued under section 10 of the BPSAA by the Management Board of Cabinet;
- the Hospital’s compliance with any applicable perquisite directives issued under section 11.1 of the BPSAA by the Management Board of Cabinet; and
- the Hospital’s compliance with any applicable procurement directives issued under section 12 of the BPSAA by the Management Board of Cabinet,

during the Applicable Period.

In making this attestation, I have exercised care and diligence that would reasonably be expected of a President & CEO in these circumstances, including making due inquiries of Hospital staff that have knowledge of these matters.



Dryden Regional Health Centre

58 GOODALL STREET, P.O. BOX 3003, DRYDEN, ONTARIO P8N 2Z6

TELEPHONE (807)223-8200 FAX (807)223-8628

Respect • Integrity • Humility • Compassion • Accountability

I further certify that any material exceptions to this attestation are documented in the attached Schedule A.

Dated at Dryden, Ontario this June 23, 2025.

Doreen Armstrong-Ross
President & CEO
Dryden Regional Health Centre

I certify that this attestation has been approved by the board of the Dryden Regional Health Centre on June 23, 2025.

Vanessa Simpson
Chair of the Board
Dryden Regional Health Centre



Dryden Regional Health Centre

58 GOODALL STREET, P.O. BOX 3003, DRYDEN, ONTARIO P8N 2Z6

TELEPHONE (807)223-8200 FAX (807)223-8628

Respect • Integrity • Humility • Compassion • Accountability

SCHEDULE A to Attestation

Material Exception to Declare

1. Exceptions to the completion and accuracy of reports required in section 6 of the BPSAA on the use of consultants;

No Known Exceptions.

2. Exceptions to the Hospital's compliance with the prohibition in section 4 of the BPSAA on engaging lobbyist services using public funds;

No Known Exceptions.

3. Exceptions to the Hospital's compliance with the expense claims directive issued under section 10 of the BPSAA by the Management Board of Cabinet;

No Known Exceptions.

4. Exceptions to the Hospital's compliance with the perquisites directive issued under section 11.1 of the BPSAA by the Management Board of Cabinet; and

No Known Exceptions.

5. Exceptions to the Hospital's compliance with the procurement directive issued under section 12 of the BPSAA by the Management Board of Cabinet.

No Known Exceptions.

6. Exceptions to the Hospital's compliance with the business plans directive issued under section 13 of the BPSAA by the Management Board of Cabinet.

No Known Exceptions.

Vanessa Simpson
Chair of the Board
Dryden Regional Health Centre

March 25, 2025

Attestation to the BPSAA Supply Chain Secretariat BPS Directive and Canada Free Trade Agreement (CFTA) Compliance

Dear Member,

Mohawk Medbuy Corporation fully understands and abides by the Ontario Ministry of Finance Broader Public Sector Supply Chain Directives and the Canada Free Trade Agreement (CFTA) meant to ensure that publicly funded goods and services are acquired by BPS organizations through a process that is open, fair, and transparent.

On behalf of Mohawk Medbuy Corporation, we attest that all contracting services performed on the Members' behalf for the applicable period of April 1, 2024 – March 31, 2025, are in compliance with the Broader Public Sector Supply Chain Directives and the Canada Free Trade Agreement (CFTA). Exceptions, for contracts on which the Member participated occurring during the twelve (12) month reporting period are noted on the attached document with supporting explanations.

In making this attestation, we have exercised care and diligence that would reasonably be expected in these circumstances, including making due inquiries and reviewing results of the self-assessment audits we have completed.

I, Marc Lemaire, Senior Vice President, Strategic Sourcing, I, Dale Thomson, Senior Vice President, National Programs & Sourcing Operations, I, Raechel Griffin, Vice President, Capital, FFE, and Nutrition Services Procurement I, Ally Dhalla, Senior Vice President Pharmacy and Clinical Services & Innovation have the signing authority to make this commitment on behalf of Mohawk Medbuy Corporation.

MOHAWK MEDBUY CORPORATION



Marc Lemaire
Senior Vice President, Strategic
Sourcing
mlemaire@mohawkmedbuy.ca



Dale Thomson
Senior Vice President, National
Programs & Sourcing
Operations
dthomson@mohawkmedbuy.ca



Raechel Griffin
Vice President, Capital, FFE
and Nutrition Services
Procurement
rgriffin@mohawkmedbuy.ca



Ally Dhalla
Senior Vice President, Pharmacy and Clinical Services & Innovation
adhalla@mohawkmedbuy.ca

BPS Attestation Report - April 1, 2024 to March 31, 2025 - DGDH

* Reported Spend indicates Member provided data for the Attestation Period. Note that contracts may have started or ended at various points within the Attestation period. Data compiled from October 2023 to September 2024

P - ND indicates Member participation on contract, however spend data not provided/available.
NP - Not Participating

DGDH

DRYDEN REGIONAL
HEALTH CENTRE

Code	Contract No.	Contract Name	Supplier Name	Contract Start Date	Current Contract Expiry Date	New Contract Expiry Date (for extended contracts)	Exception Type	Justification Code	SC10046
MMCL	C10012	MMCL BLOOD TUBES 2017 - GBO - PA	GREINER BIO ONE	April 1, 2017	March 31, 2024	December 31, 2025	Appendix A - Limited Tender	C(i) C(ii)	P-ND
OR	C10047	OR BASIC SURGICAL INSTRUMENTS 2017 - INTEGRA	INTEGRA CANADA ULC	December 1, 2017	November 30, 2024	January 31, 2025	Appendix A - Limited Tender	D	P-ND
OR	C10181	OR LASER FIBERS 2017 - CLARION MEDICAL - PA	CLARION MEDICAL TECHNOLOG	November 1, 2017	July 31, 2024	January 31, 2026	Appendix A - Limited Tender	D	P-ND
OR	C10220	OR SKIN PREP SYSTEMS 2018 - 3M CANADA	3M HEALTHCARE CANADA COM	June 1, 2018	May 31, 2024	July 31, 2024	Appendix A - Limited Tender	D	P-ND
OR	C10221	OR SKIN PREP SYSTEMS 2018 - BECTON DICKINSON	BECTON DICKINSON CANADA I	June 1, 2018	May 31, 2024	July 31, 2024	Appendix A - Limited Tender	D	P-ND
OR	C10222	OR SKIN PREP SYSTEMS 2018 - CARDINAL HEALTH	CARDINAL HEALTH CANADA IN	June 1, 2018	May 31, 2024	July 31, 2024	Appendix A - Limited Tender	D	P-ND
OR	C10223	OR SKIN PREP SYSTEMS 2018 - MEDLINE CANADA	MEDLINE CANADA INC.	June 1, 2018	May 31, 2024	July 31, 2024	Appendix A - Limited Tender	D	P-ND
OR	C10224	OR SKIN PREP SYSTEMS 2018 - MEDLINE	MEDLINE CANADA INC.	June 1, 2018	May 31, 2024	July 31, 2024	Appendix A - Limited Tender	D	P-ND
OR	C10225	OR SKIN PREP SYSTEMS 2018 - OMEGA LABORATORIES	OMEGA LABORATORIES LTD.	June 1, 2018	May 31, 2024	July 31, 2024	Appendix A - Limited Tender	D	P-ND
MMCL	C10257	MMCL CORE UROLOGY PRODUCTS 2018 - MEDLINE	MEDLINE CANADA INC.	October 1, 2018	September 30, 2024	December 31, 2024	Appendix A - Limited Tender	D	P-ND
MMCL	C10258	MMCL CORE UROLOGY PRODUCTS 2018 - BARD	BARD CANADA INC	October 1, 2018	September 30, 2024	December 31, 2024	Appendix A - Limited Tender	D	P-ND
OR	C10260	OR HERNIA REPAIR PRODUCTS 2018 - BARD	BARD CANADA INC	November 1, 2018	October 31, 2024	January 31, 2025	Appendix A - Limited Tender	D	P-ND
OR	C10262	OR HERNIA REPAIR PRODUCTS 2018 - MEDTRONIC	MEDTRONIC CANADA -ULC.	November 1, 2018	October 31, 2024	January 31, 2025	Appendix A - Limited Tender	D	P-ND
OR	C10263	OR HERNIA REPAIR PRODUCTS 2018 - JJMP	JOHNSON & JOHNSON MEDTE	November 1, 2018	October 31, 2024	January 31, 2025	Appendix A - Limited Tender	D	P-ND
MMNCL	C10283	MMNCL STERILIZATION AND ENDOSCOPIC REPROCESSING PRODUCTS 2016	CANADIAN HOSPITAL SPECIAL	May 10, 2018	December 31, 2024	September 30, 2025	Appendix A - Limited Tender	D	P-ND
MMCL	C10287	MMCL TRAYS 2018 - CARDINAL	CARDINAL HEALTH CANADA IN	October 1, 2018	September 30, 2024	December 31, 2024	Appendix A - Limited Tender	D	P-ND
INNOV	C10290	INNOV GEKO 2018 PA - TRUDELL MEDICAL MARKETING LTD	TRUDELL MEDICAL MARKETIN	August 1, 2028	July 31, 2024	July 31, 2026	Appendix A - Limited Tender	B(iii)	P-ND
OR	C10381	OR BIOLOGIC MESH 2018 - ABBVIE	ABBVIE CORPORATION	November 1, 2018	October 31, 2024	January 31, 2025	Appendix A - Limited Tender	D	P-ND
OR	C10387	OR BIOLOGIC MESH 2018 - MEDTRONIC CANADA	MEDTRONIC CANADA -ULC.	November 1, 2018	October 31, 2024	January 31, 2025	Appendix A - Limited Tender	D	P-ND
MMNCL	C10452	MMNCL DRY CELL BATTERIES 2019 - CARDINAL	CARDINAL HEALTH	April 1, 2019	March 31, 2024	November 30, 2024	Appendix A - Limited Tender	D	P-ND
MMNCL	C10500	MMNCL CHEMICALS - DIETARY & LAUNDRY 2019 - BUNZL	BUNZL CANADA INC	September 1, 2019	August 31, 2024	August 30, 2026	Appendix A - Limited Tender	D	P-ND
MMCL	C10654	MMCL BREAST PUMPS & ACCESSORIES 2019 - MEDELA	MEDELA CANADA INC.	November 1, 2019	January 31, 2025	July 31, 2025	Appendix A - Limited Tender	D	P-ND
PH	C10865	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS BHC 2020	BAUSCH HEALTH, CANADA INC	June 9, 2023	January 31, 2024		Appendix A - Limited Tender	B	P-ND
PH	C10958	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS NEG GSK 2021	GLAXOSMITHKLINE	June 1, 2023	January 31, 2024		Appendix A - Limited Tender	B	P-ND
OR	C11035	OR SPONGES 2021 - MEDLINE - PA	MEDLINE	March 1, 2021	May 31, 2024	November 30, 2024	Appendix A - Limited Tender	D	P-ND
OR	C11038	OR SPONGES 2021 - MEDQUEST - PA	MEDQUEST (WAS STEVENS)	March 1, 2021	May 31, 2024	November 30, 2024	Appendix A - Limited Tender	D	P-ND
MILR	C11140	MILR TEST URINALYSIS 2021 - SIEMENS - PA	SIEMENS HEALTHCARE LIMITE	July 1, 2021	June 30, 2024	August 31, 2024	Appendix A - Limited Tender	D	P-ND
PH	C11175	PH INJECTABLE PHARMACEUTICALS NEG BAX 2021	BAXTER CORPORATION	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
PH	C11216	PH INJECTABLE PHARMACEUTICALS AURO 2021	AURO PHARMA INC.	June 19, 2023	September 30, 2024		Appendix A - Limited Tender	B	P-ND
PH	C11223	PH INJECTABLE PHARMACEUTICALS FRK 2021	FRESENIUS KABI CANADA LTD	March 17, 2024	September 30, 2024		Appendix A - Limited Tender	B	P-ND
PH	C11230	PH INJECTABLE PHARMACEUTICALS MTP 2021	METHAPHARM	August 25, 2023	September 30, 2024		Appendix A - Limited Tender	B	P-ND
PH	C11234	PH INJECTABLE PHARMACEUTICALS OME 2021	OMEGA LABORATORIES LTD.	August 21, 2023	September 30, 2024		Appendix A - Limited Tender	B	P-ND
PH	C11307	PH RESERVE INJECTABLE PHARMACEUTICALS JAMP 2021	JAMP PHARMA CORPORATION	May 5, 2023	September 30, 2024		Appendix A - Limited Tender	B	P-ND
PH	C11336	PH INJECTABLE MICRONUTRIENTS BAX 2021	BAXTER CORPORATION	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
PH	C11427	PH INJECTABLE PHARMACEUTICALS AGT 2022	LABORATOIRE AGUETTANT CA	April 28, 2023	September 30, 2024		Appendix A - Limited Tender	B	P-ND
PH	C11547	PH ONCOLOGY MEDU 2022	MEDUNIK CANADA	January 1, 2025	September 30, 2025		Appendix A - Limited Tender	B(ii)	P-ND
PH	C11557	PH PARENTERAL NUTRITION SOLUTIONS + LIPIDS FRK 2022	FRESENIUS KABI CANADA LTD.	July 14, 2023	October 31, 2025		Appendix A - Limited Tender	B	P-ND
PH	C11579	PH ONCOLOGY APX 2022	APOTEX INC	January 1, 2025	September 30, 2025		Appendix A - Limited Tender	B(ii)	P-ND
PH	C11580	PH ONCOLOGY ASP 2022	ASPEN PHARMACARE CANADA	January 1, 2025	September 30, 2025		Appendix A - Limited Tender	B(ii)	P-ND
PH	C11582	PH ONCOLOGY BAX 2022	BAXTER CORPORATION	January 1, 2025	September 30, 2025		Appendix A - Limited Tender	B(ii)	P-ND
PH	C11585	PH ONCOLOGY SPI 2022	SEARCHLIGHT PHARMA INC.	January 1, 2025	September 30, 2025		Appendix A - Limited Tender	B(ii)	P-ND
PH	C11586	PH ONCOLOGY FRK 2022	FRESENIUS KABI CANADA LTD.	January 1, 2025	September 30, 2025		Appendix A - Limited Tender	B(ii)	P-ND
PH	C11587	PH ONCOLOGY GMP 2022	GENERIC MEDICAL PARTNERS	January 1, 2025	September 30, 2025		Appendix A - Limited Tender	B(ii)	P-ND
PH	C11588	PH ONCOLOGY MAR 2022	MARCAN PHARMACEUTICALS I	January 1, 2025	September 30, 2025		Appendix A - Limited Tender	B(ii)	P-ND
PH	C11590	PH ONCOLOGY NAT 2022	NATCO PHARMA (CANADA) INC	January 1, 2025	September 30, 2025		Appendix A - Limited Tender	B(ii)	P-ND
PH	C11596	PH ONCOLOGY SAV 2022	SANOFI-AVENTIS CANADA INC.	January 1, 2025	September 30, 2025		Appendix A - Limited Tender	B(ii)	P-ND
PH	C11597	PH ONCOLOGY TAR 2022	TARO PHARMACEUTICALS INC	January 1, 2025	September 30, 2025		Appendix A - Limited Tender	B(ii)	P-ND
PH	C11599	PH ONCOLOGY YLO 2022	VALEO PHARMA	January 1, 2025	September 30, 2025		Appendix A - Limited Tender	B(ii)	P-ND
PH	C11623	PH RESERVE ONCOLOGY APX 2022	APOTEX INC	January 1, 2025	September 30, 2025		Appendix A - Limited Tender	B(ii)	P-ND
MMCL	C11634	PH RESERVE ONCOLOGY STM 2022	STERIMAX	January 1, 2025	September 30, 2025		Appendix A - Limited Tender	B(ii)	P-ND
PH	C11643	PH RESERVE ONCOLOGY PFI 2022	PFIZER CANADA ULC	January 1, 2025	September 30, 2025		Appendix A - Limited Tender	B(ii)	P-ND
PH	C11648	PH RESERVE ONCOLOGY JAMP 2022	JAMP PHARMA CORPORATION	January 1, 2025	September 30, 2025		Appendix A - Limited Tender	B(ii)	P-ND
PH	C11715	PH PHARMACY SUPPLIES PHS 2022	PHARMASYSTEMS INC.	November 1, 2023	November 30, 2025		Appendix A - Limited Tender	B	P-ND
PH	C11861	PH PREFILLED LOCK FLUSH SYRINGES + DEVICES BD 2023	BECTON DICKINSON CANADA I	May 1, 2023	April 30, 2026	December 31, 2028	Appendix A - Limited Tender	B	P-ND
PH	C11871	PH ORAL SOLID PHARMACEUTICALS APX 2023	APOTEX INC	July 1, 2023	March 31, 2027		Appendix A - Limited Tender	B	P-ND
PH	C11899	PH ORAL SOLID PHARMACEUTICALS TEVA 2023	TEVA CANADA LIMITED INC	July 1, 2023	March 31, 2027		Appendix A - Limited Tender	B	P-ND
PH	C12122	PH BIOSIMILAR ONCOLOGY NCCNEG ORG 2023	ORGANON CANADA INC.	July 1, 2023	September 30, 2024		Appendix A - Limited Tender	B	P-ND
PH	C12158	PH ONCOLOGY EISAI 2023	EISAI LIMITED	February 1, 2024	September 30, 2025		Appendix A - Limited Tender	B	P-ND
PH	C12170	PH INJECTABLE PHARMACEUTICALS IUL 2023	INDIVIOR CANADA LTD.	September 26, 2023	September 30, 2024		Appendix A - Limited Tender	B	P-ND
PH	C12283	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS BALC 2024	BAUSCH + LOMB CORPORATIO	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
PH	C12293	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS KEN 2024	KENVUE CANADA INC.	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	B	P-ND
PH	C12300	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS NOR 2024	NORWELL CONSUMER HEALTH	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
PH	C12301	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS NVR 2024	NOVARTIS PHARMACEUTICALS	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
PH	C12306	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS PDL 2024	PALADIN PHARMA INC.	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
PH	C12317	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS TEVA 2024	TEVA CANADA LIMITED INC	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
PH	C12318	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS VLO 2024	VALEO PHARMA	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND

PH	C12407	PH RESERVE NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS AUR	AURO PHARMA INC.	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
PH	C12408	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS STOM 2024	STOM PHARMA INC.	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
PH	C12415	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS HTH 2024	HEALTHMARK SERVICES	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
PH	C12424	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS SPI 2024	SEARCHLIGHT PHARMA INC.	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
PH	C12425	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS ATL 2024	ATLAS LABORATOIRE INC.	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
PH	C12426	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS SFR 2024	SEAFORD PHARMACEUTICALS	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
PH	C12436	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS LEO 2024	LEO PHARMA INC	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
PH	C12442	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS IUL 2024	INDIVIOR CANADA LTD.	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
PH	C12475	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS ESS 2023	ESSENTIAL PHARMA	December 15, 2023	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
PH	C12478	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS COVIS 2024	COVIS PHARMA CANADA LTD.	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
PH	C12483	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS AAP 2024	AA PHARMA INC.	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
PH	C12520	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS ALC 2024	ALCON CANADA INC.	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
PH	C12523	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS KNI 2024	KNIGHT THERAPEUTICS INC.	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
PH	C12541	PH ERYTHROPOIESIS STIMULATING AGENTS NCCNEG AMG 2024	AMGEN CANADA INC.	July 1, 2024	June 30, 2027		Appendix A - Limited Tender	B	P-ND
PH	C12542	PH ERYTHROPOIESIS STIMULATING AGENTS NCCNEG JAN 2024	JANSSEN INC.	July 1, 2024	June 30, 2027		Appendix A - Limited Tender	B	P-ND
PH	C12690	PH INJECTABLE PHARMACEUTICALS BAY 2024 EXCLUSIVE	BAYER INC.	July 1, 2024	September 30, 2024		Appendix A - Limited Tender	C(ii)	P-ND
PH	C12733	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS NCCNEG ON HL	HOFFMANN-LA ROCHE LIMITED	February 20, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
MILR	C12749	MILR TEST URINALYSIS 2024 - SIEMENS - PA	SIEMENS HEALTHCARE LIMITED	September 1, 2024	August 8, 2027		Appendix A - Limited Tender	B(v)	P-ND
PH	C12780	PH ONCOLOGY EPI 2024	EUGIA PHARMA INC.	January 1, 2025	September 30, 2025		Appendix A - Limited Tender	B(ii)	P-ND
PH	C12943	PH BIOLOGIC AND BIOSIMILAR INJECTABLE PHARMACEUTICALS SDZ 2024	SANDOZ CANADA INC	October 1, 2024	May 31, 2027		Appendix A - Limited Tender	A(i)	P-ND
PH	C12951	PH INJECTABLE PHARMACEUTICALS ASP 2024	ASPEN PHARMACARE CANADA	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
PH	C12953	PH INJECTABLE PHARMACEUTICALS AVIR 2024	AVIR PHARMA INC.	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
PH	C12959	PH INJECTABLE PHARMACEUTICALS HCL 2024	HIKMA CANADA LTD.	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
PH	C12967	PH INJECTABLE PHARMACEUTICALS MTP 2024	METHAPHARM	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
PH	C12972	PH INJECTABLE PHARMACEUTICALS PFI 2024	PFIZER CANADA ULC	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
PH	C12979	PH INJECTABLE PHARMACEUTICALS STM 2024	STERIMAX	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
PH	C13032	PH SEVOFLURANE INHALATION ANESTHETIC ABB 2024	ABBVIE CORPORATION	October 1, 2024	September 30, 2026		Appendix A - Limited Tender	A5 (v)	P-ND
PH	C13033	PH SEVOFLURANE INHALATION ANESTHETIC BAX 2024	BAXTER CORPORATION	October 1, 2024	September 30, 2026		Appendix A - Limited Tender	A5 (v)	P-ND
PH	C13034	PH SEVOFLURANE INHALATION ANESTHETIC CHS 2024	CANADIAN HOSPITAL SPECIALTIES LTD.	October 1, 2024	September 30, 2026		Appendix A - Limited Tender	A5 (v)	P-ND
PH	C13054	PH INJECTABLE PHARMACEUTICALS GMP 2024	GENERIC MEDICAL PARTNERS	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
PH	C13164	PH RESERVE INJECTABLE PHARMACEUTICALS MAR 2024	MARCAN PHARMACEUTICALS INC.	January 1, 2025	May 31, 2028		Appendix A - Limited Tender	B(ii)	P-ND
PH	C13176	PH RESERVE INJECTABLE PHARMACEUTICALS JAMP 2024	JAMP PHARMA CORPORATION	January 1, 2025	May 31, 2028		Appendix A - Limited Tender	B(ii)	P-ND
PH	C13178	PH ONCOLOGY PHARMACEUTICALS AND 2024	ANDONE PHARMACEUTICALS INC.	January 1, 2025	September 30, 2025		Appendix A - Limited Tender	B(ii)	P-ND
PH	C13184	PH RESERVE INJECTABLE PHARMACEUTICALS ASP 2024	ASPEN PHARMACARE CANADA	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
PH	C13212	PH RESERVE INJECTABLE PHARMACEUTICALS RDY 2024	DR. REDDY'S LABORATORIES LTD.	January 1, 2025	May 31, 2028		Appendix A - Limited Tender	B(ii)	P-ND
PH	C13324	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS BCE 2024	BCE PHARMA INC.	November 1, 2024	November 30, 2026		Appendix A - Limited Tender	Article 513 (b) (ii)	P-ND
PH	C13326	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS HFS 2024	H.E.P.A. FILTER SERVICES INC.	November 1, 2024	November 30, 2026		Appendix A - Limited Tender	Article 513 (b) (ii)	P-ND
PH	C13327	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024	SUPERIOR TESTING SERVICES	November 1, 2024	November 30, 2026		Appendix A - Limited Tender	Article 513 (b) (ii)	P-ND
PH	C13341	PH ONCOLOGY SS PFI 2024	PFIZER CANADA ULC	October 1, 2024	September 30, 2025		Appendix A - Limited Tender	B(ii)	P-ND
PH	C13463	PH INJECTABLE PHARMACEUTICALS ORG 2024	ORGANON CANADA INC.	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
PH	C13464	PH INJECTABLE PHARMACEUTICALS SFR 2024	SEAFORD PHARMACEUTICALS	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
PH	C13542	PH INJECTABLE PHARMACEUTICALS BBC 2024	B. BRAUN OF CANADA LTD	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
PH	C13615	PH INJECTABLE PHARMACEUTICALS SUM 2024	SUMITOMO PHARMA CANADA INC.	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
PH	C13689	PH INJECTABLE PHARMACEUTICALS ALC 2024	ALCON CANADA INC.	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
PH	C13690	PH INJECTABLE PHARMACEUTICALS NNO 2024	NOVO NORDISK CANADA INC.	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
PH	C13691	PH INJECTABLE PHARMACEUTICALS XED 2024	XEDITON PHARMACEUTICALS	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
PH	C13803	PH INJECTABLE PHARMACEUTICALS KNI 2024	KNIGHT THERAPEUTICS INC.	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
PH	C13804	PH INJECTABLE PHARMACEUTICALS PDL 2024	PALADIN PHARMA INC.	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
PH	C13805	PH INJECTABLE PHARMACEUTICALS HLR 2024	HOFFMANN-LA ROCHE LIMITED	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
PH	C13911	PH BIOLOGIC AND BIOSIMILAR INJECTABLE PHARMACEUTICALS LEO 2025	LEO PHARMA INC	October 1, 2024	May 31, 2027		Appendix A - Limited Tender	A(i)	P-ND
PH	C14057	PH INJECTABLE PHARMACEUTICALS NCCNEG FRK 2024	FRESENIUS KABI CANADA LTD.	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
PH	C14127	PH INJECTABLE PHARMACEUTICALS LEO 2025	LEO PHARMA INC	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
PH	C14202	PH INJECTABLE PHARMACEUTICALS LBI 2025	LEADANT BIOSCIENCES, INC.	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
OR	C8669	OR PELVIC SUPPORT PRODUCTS 2015 - BOSTON SCIENTIFIC	BOSTON SCIENTIFIC	October 1, 2015	May 31, 2024	May 31, 2025	Appendix A - Limited Tender	D	P-ND
OR	C8672	OR PELVIC SUPPORT PRODUCTS 2015 - JUMP	J&J	October 1, 2015	May 31, 2024	May 31, 2025	Appendix A - Limited Tender	D	P-ND
OR	C8673	OR PELVIC SUPPORT PRODUCTS 2015 - RED LEAF	RED LEAF MEDICAL	October 1, 2015	May 31, 2024	May 31, 2025	Appendix A - Limited Tender	D	P-ND
OR	C8914	OR SPONGES 2016 - AMD	AMD	January 1, 2017	May 31, 2024	November 30, 2024	Appendix A - Limited Tender	D	P-ND
OR	C8915	OR SPONGES 2016 - DERMA	DERMA SCIENCES	January 1, 2017	May 31, 2024	November 30, 2024	Appendix A - Limited Tender	D	P-ND
MMNCL	C8955	MMNCL STERILIZATION AND ENDOSCOPIC REPROCESSING PRODUCTS 2016	ADVANCED STERILIZATION PRODUCTS	May 1, 2016	June 30, 2025	June 30, 2025	Appendix A - Limited Tender	D	P-ND
MMNCL	C8957	MMNCL STERILIZATION AND ENDOSCOPIC REPROCESSING PRODUCTS 2016	STERIS CANADA SALES ULC	May 1, 2016	June 30, 2025	June 30, 2025	Appendix A - Limited Tender	D	P-ND
MMNCL	C8964	MMNCL IT CONSUMABLES 2016 - STAPLES	STAPLES PROFESSIONAL CANADA	June 20, 2016	June 29, 2024	June 30, 2025	Appendix A - Limited Tender	C(i)	P-ND
MMNCL	C9109	MMNCL DECONTAMINATION PRODUCTS 2017 - STERIS	STERIS	January 1, 2017	May 31, 2024	March 31, 2025	Appendix A - Limited Tender	D	P-ND
MMNCL	C9111	MMNCL DECONTAMINATION PRODUCTS 2017 - ECOLAB	ECOLAB	February 1, 2017	May 31, 2024	March 31, 2025	Appendix A - Limited Tender	D	P-ND
MMNCL	C9112	MMNCL DECONTAMINATION PRODUCTS 2017 - GETINGE CANADA LTD	GETINGE CANADA LTD	February 1, 2017	May 31, 2024	March 31, 2025	Appendix A - Limited Tender	D	P-ND
MMNCL	C9113	MMNCL DECONTAMINATION PRODUCTS 2017 - SOUTHMEDIC	SOUTHMEDIC	February 1, 2017	May 31, 2024	March 31, 2025	Appendix A - Limited Tender	D	P-ND
MMNCL	C9114	MMNCL DECONTAMINATION PRODUCTS 2017 - VANTAGE	VANTAGE ENDOSCOPY	February 1, 2017	May 31, 2024	March 31, 2025	Appendix A - Limited Tender	D	P-ND
MMCL	MSS-1660	MMCL CATHETER URETHRAL URINARY	COLOPLAST CANADA CORPORATION	March 1, 2015	September 30, 2024	December 31, 2024	Appendix A - Limited Tender	D	P-ND

Report Definitions and Reference Tables

* Reported Spend indicates Member provided data for the Attestation Period. Note that contracts may have started or ended at various points within the Attestation period. Data compiled from October 2023 to September 2024.

P - ND indicates Member participation on contract, however spend data not provided/available.

NP - Not Participating

Appendix A – Limited Tendering (Article 513)	
	Limited Tendering: means a procurement method whereby the procuring entity contacts a supplier or suppliers of its choice. In accordance with the CFTA Chapter 5 (Government Procurement), an organization may use Limited Tendering in the following circumstances, provided that it does not use this provision for the purpose of avoiding competition among suppliers or in a manner that discriminates against suppliers or any other Party or protects its own suppliers.
	<input type="checkbox"/> (a) if:
A(i)	<input type="checkbox"/> (i) no tenders were submitted or no suppliers requested participation;
A(ii)	<input type="checkbox"/> (ii) no tenders that conform to the essential requirements of the tender documentation were submitted;
A(iii)	<input type="checkbox"/> (iii) no suppliers satisfied the conditions for participation; or
A(iv)	<input type="checkbox"/> (iv) the submitted tenders were collusive
	provided that the requirements of the tender documentation are not substantially modified;
	<input type="checkbox"/> (b) if the goods or services can be supplied only by a particular supplier and no reasonable alternative or substitute goods or services exist for any of the following reasons:
B(i)	<input type="checkbox"/> (i) the requirement is for a work of art;
B(ii)	<input type="checkbox"/> (ii) the protection of patents, copyrights, or other exclusive rights;
B(iii)	<input type="checkbox"/> (iii) due to an absence of competition for technical reasons;
B(iv)	<input type="checkbox"/> (iv) the supply of goods or services is controlled by a supplier that is a statutory monopoly;
B(v)	<input type="checkbox"/> (v) to ensure compatibility with existing goods, or to maintain specialized goods that must be maintained by the manufacturer of these goods or its representative;
B(vi)	<input type="checkbox"/> (vi) work is to be performed on property by a contractor according to provisions of a warranty or guarantee held in respect of the property or the original work;
B(vii)	<input type="checkbox"/> (vii) work is to be performed on a leased building or related property, or portions thereof, that may be performed only by the lessor; or
B(viii)	<input type="checkbox"/> (viii) the procurement is for subscriptions to newspapers, magazines, or other periodicals;
	<input type="checkbox"/> (c) for additional deliveries by the original supplier of goods or services that were not included in the initial procurement, if a change of supplier for such additional goods or services:
C(i)	<input type="checkbox"/> (i) cannot be made for economic or technical reasons such as requirements of interchangeability or interoperability with existing equipment, software, services, or installations procured under the initial procurement; and
C(ii)	<input type="checkbox"/> (ii) would cause significant inconvenience or substantial duplication of costs for the procuring entity;
D	<input type="checkbox"/> (d) if strictly necessary, and for reasons of urgency brought about by events unforeseeable by the procuring entity, the goods or services could not be obtained in time using open tendering;
E	<input type="checkbox"/> (e) for goods purchased on a commodity market;
	<input type="checkbox"/> (f) if a procuring entity procures a prototype or a first good or service that is developed in the course of, and for, a particular contract for research, experiment, study, or original development. Original development of a first good or service may include limited production or supply in order to incorporate the results of field testing and to demonstrate that the good or service is suitable for production or supply in quantity to acceptable quality standards, but does not include quantity production or supply to establish commercial viability or to recover research and development costs;
F	<input type="checkbox"/> (g) for purchases made under exceptionally advantageous conditions that only arise in the very short term in the case of unusual disposals such as those arising from liquidation, receivership, or bankruptcy, but not for routine purchases from regular suppliers;
G	<input type="checkbox"/> (h) if a contract is awarded to a winner of a design contest provided that:
H(i)	<input type="checkbox"/> (i) the contest has been organized in a manner that is consistent with the principles of this Chapter, in particular relating to the publication of a tender notice; and
H(ii)	<input type="checkbox"/> (ii) the participants are judged by an independent jury with a view to a design contract being awarded to a winner; or
I	<input type="checkbox"/> (i) if goods or consulting services regarding matters of a confidential or privileged nature are to be purchased and the disclosure of these matters through an open tendering process could reasonably be expected to compromise government confidentiality, result in the waiver of privilege, cause economic disruption, or otherwise be contrary to the public interest.
Appendix B – Non-Application (Article 504)	
	Non-Application: means the CFTA Chapter 5 (Government Procurement) does not apply to:
A	<input type="checkbox"/> (a) public employment contracts;
B	<input type="checkbox"/> (b) non-legally binding agreements;
C	<input type="checkbox"/> (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives;
D	<input type="checkbox"/> (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part, by the organization, only to the extent that the agreement includes rules for awarding contracts that differ from the obligations of this Chapter;
E	<input type="checkbox"/> (e) acquisition or rental of land, existing buildings, or other immovable property, or the rights thereon;
F	<input type="checkbox"/> (f) measures necessary to protect intellectual property, provided that the measures are not applied in a manner that would constitute a means of arbitrary or unjustifiable discrimination between Parties where the same conditions prevail or are a disguised restriction on trade;
	<input type="checkbox"/> (g) procurement or acquisition of:
G(i)	<input type="checkbox"/> (i) fiscal agency or depository services;
G(ii)	<input type="checkbox"/> (ii) liquidation and management services for regulated financial institutions; or
G(iii)	<input type="checkbox"/> (iii) services related to the sale, redemption, and distribution of public debt, including loans and government bonds, notes, and other securities;
	<input type="checkbox"/> (h) procurement of:
H(i)	<input type="checkbox"/> (i) financial services respecting the management of government financial assets and liabilities (i.e. treasury operations), including ancillary advisory and information services, whether or not delivered by a financial institution;
H(ii)	<input type="checkbox"/> (ii) health services or social services;
H(iii)	<input type="checkbox"/> (iii) services that may, under applicable law, only be provided by licensed lawyers or notaries; or
H(iv)	<input type="checkbox"/> (iv) services of expert witnesses or factual witnesses used in court or legal proceedings; or
	<input type="checkbox"/> (i) procurement of goods or services:
I(i)	<input type="checkbox"/> (i) financed primarily from donations that require the procurement to be conducted in a manner inconsistent with this Chapter;
I(ii)	<input type="checkbox"/> (ii) by a procuring entity on behalf of an entity not covered by this Chapter;
I(iii)	<input type="checkbox"/> (iii) between enterprises that are controlled by or affiliated with the same enterprise, or between one government body or enterprise and another government body or enterprise;
I(iv)	<input type="checkbox"/> (iv) by non-governmental bodies that exercise governmental authority delegated to them;
I(v)	<input type="checkbox"/> (v) from philanthropic institutions, non-profit organizations, prison labour, or natural persons with disabilities;
	<input type="checkbox"/> (vi) under a commercial agreement between a procuring entity which operates sporting or convention facilities and an entity not covered by this Chapter that contains provisions inconsistent with this Chapter;
I(vi)	<input type="checkbox"/> (vi) conducted for the specific purpose of providing international assistance, including development aid, provided that the procuring entity does not discriminate on the basis of origin or location within Canada of goods, services, or suppliers; or
I(vii)	<input type="checkbox"/> (vii) conducted:
I(viii)	<input type="checkbox"/> (A) under the particular procedure or condition of an international agreement relating to the stationing of troops or relating to the joint implementation by the signatory countries of a project; or
I(viii)	<input type="checkbox"/> (B) under the particular procedure or condition of an international organization, or funded by international grants, loans, or other assistance, if the procedure or condition would be inconsistent with this Chapter.

APPENDIX A – HOSPITAL REPORT ON CONSULTANT USE

Name of Hospital: Dryden Regional Health Centre

OH Region: North

Reporting Period: April 1, 2024 to March 31, 2025

No.	Consultant Firm Name(s)	Name and Title of Consulting Contract	Contract Term If the contract term has been extended, please include the original contract term and the amended contract term	Procurement Value (A) Original value plus (B) Value of amendments and (C) Total procurement value (\$) / Total Paid	Consultant Selection Process (Open Competitive, Invitational Competitive, Non-competitive) If non-competitive, please provide an explanation	Modifications to Agreement (Yes/No) If Yes, did the procurement documents permit modifications to the term or value of the agreement?
1.	MNP LLP	Audit Service	April 1, 2024 to March 31, 2025	Total Paid for the Reporting Period = \$38,110	Invitational Competitive	No
2.	Mondelis Actuarial Services	Post-Employment Benefits	April 1, 2024 to March 31, 2025	Total Paid for the Reporting Period = \$1,525	Open Competitive	No
3.	Blackstone	Natural Gas and Electricity Procurement Advisor Services and Reporting	December 2024 to October 2026	Total Paid for the Reporting Period = \$109,251	Open Competitive	No
4.	807 Management	Financial Services	December 1, 2023 to June 30, 2024 Amended to July 31, 2024	Total Paid for the Reporting Period = \$49,720	Non-Competitive; CFO vacancy resulted in need for interim CFO services.	No
5.	NRG Management	Chiller Replacement Project	To project completion	Total Paid for the Reporting Period = \$322,752	Open Competitive	No
6.	Colliers Project Leaders Inc.	Pharmacy Project Management	To project completion	Total Paid for the Reporting Period = \$161,260	Open Competitive	No

Preservation of Solicitor –client privilege:

This legislation maintains the integrity of solicitor client privilege, litigation privilege and settlement privilege, and does not require the disclosure of information subject to any of these privileges.

While hospitals are expected to report on their retention of lawyers and law firms for the provision of consulting services, they are not required to report on instances where they have retained lawyers and law firms to provide legal advice, draft legal documents, conduct litigation on behalf of a hospital, or otherwise for the purpose of providing legal services to a hospital.